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Abstract
We previously demonstrated that the CDR1 gene, encoding a multidrug transporter in Candida albicans, is differentially
upregulated by various drugs and steroids. In order to get an insight into the molecular basis of the induction of this gene we
analyzed its promoter region. The transcription start site was mapped to 63 nucleotides upstream of the initiating ATG.
Reporter assays revealed the presence of four upstream activating and four upstream repressing sequence domains along the
entire promoter. Like the native gene, promoter-luciferase recombinants showed enhanced activity in response to various
stresses like drugs, human steroid hormones and heavy metals. Mutational analysis demonstrated that while the proximal
promoter (3345/+1) contains all the regulatory domains required for its induction by various other stresses, the miconazole
response is mediated via the distal promoter (3857/31147), harboring an AP-1 site. The involvement of the AP-1 element in
mediating the latter effect was evident by an increase in AP-1 binding activity following miconazole treatment. ß 1999
Federation of European Microbiological Societies. Published by Elsevier Science B.V. All rights reserved.
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1. Introduction
In spite of the widespread occurrence of the ABC
(ATP binding cassette) and MFS (major facilitator
superfamily) genes and their involvement in confer-
ring multidrug resistance (MDR) in Candida albi-
cans, the molecular mechanisms controlling their ex-
pression is poorly understood [1]. In contrast, the
regulatory network controlling the expression of
the MDR genes in Saccharomyces cerevisiae is rela-
tively well elucidated [2]. For example, it is known
that the expression of PDR5, the functional homo-
logue of CDRI, is under the control of two tran-
scription factors, viz. PDR1 and PDR3 [3]. Recently,
Raymond and coworkers have identi¢ed a family of
transcription regulators named FCRs in C. albicans,
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which appear to be the functional homologues of
Pdr1/Pdr3. Among them, at least one, viz. FCR1,
functions as a negative regulator of MDRs [4]. How-
ever, the plausible targets of FCR genes remain to be
identi¢ed. CAP1, a b-Zip transcription factor and a
homologue of YAP1 in S. cerevisiae, has also been
implicated in conferring resistance to multiple drugs
and to oxidative stress in C. albicans [5].
We have earlier demonstrated that at least two of
the C. albicans MDR genes, CDR1 and CaMDR1,
are transcriptionally activated to various extents by
di¡erent environmental stresses [6,7]. However, the
molecular basis of their activation by those agents
is yet to be established [4,8]. As a long-term goal
to unravel the regulatory mechanism(s) which con-
trols the expression of MDR genes in C. albicans, we
have characterized for the ¢rst time the 5P £anking
sequence of the CDR1 gene. Our results demonstrate
that CDR1 gene expression is under the complex
control of multiple positively and negatively acting
cis-regulatory elements. We also demonstrate that
the regulatory domains responding to the induction
by various drugs are clustered in the proximal region
(3345/+1) except for the miconazole-responsive do-
main that is located in the distal part (3857/31147)
of the promoter.
2. Materials and methods
2.1. Strains
C. albicans ATCC 10261 was used for preparing
nuclear extracts and RNA isolation. C. albicans
strain Red 3/6 (purchased from David Soll, Univer-
sity of Iowa, USA), an ade2 derivative of strain WO-
1, was maintained on YNB medium supplemented
with 3 mM adenine sulfate and was used for reporter
assay [9].
2.2. Primer extension analysis
Total RNA was isolated from a C. albicans strain
(ATCC 10261) grown to mid-exponential phase fol-
lowing treatment with 100 Wg ml31 miconazole.
RNA (50 Wg) was hybridized at 50‡C overnight
with 1.25 pmol of the labeled primer complementary
to the region following the ¢rst ATG (see Fig. 1A).
The hybrid was then precipitated and reverse tran-
scribed using AMV-Reverse transcriptase (Boeh-
ringer Mannheim) for 60 min at 42‡C according to
the manufacturer’s protocol. The reaction was
stopped, and the pelleted DNA was resuspended in
0.1 N NaOH and 0.5 M EDTA for 25 min at 30‡C.
The DNA was then denatured and electrophoresed
on a 6% sequencing gel in a parallel lane along with
the dideoxy sequencing reactions performed with the
same primer.
2.3. Construction of 5P deletion mutants of the CDR1
promoter
The 1147-bp CDR1 promoter was cloned into
pCRW3, a luciferase reporter plasmid, in two steps.
First the proximal 331-bp DraI-SacI fragment was
cloned into its SmaI-SacI site and then the distal
854-bp SacI-SacI fragment was introduced in the
right orientation to give the full-length promoter-re-
porter recombinant. Due to the unavailability of
suitable restriction sites for deletions, the 1.14-kb
promoter fragment was subcloned into pBluescript
(KS), the recombinant was linearized with XhoI
and ApaI and deletions were made using exonuclease
III from the XhoI site. The deletion points were de-
termined by sequencing the deletion ends, the se-
lected fragments were released by PstI-KpnI diges-
tion and cloned into the reporter vector pCRW3.
2.4. Transformation and in vitro assay of luciferase
activity
C. albicans strain Red 3/6 was electroporated ac-
cording to the method described by Kohler et al.
[10]. Transformants appearing after 3^4 days were
screened by Southern analysis using the 1.1-kb
Rluc fragment (of the Renilla luciferase gene) as
the probe. The luciferase reporter assay was essen-
tially done as described by Srikantha et al. [9] using a
TD 20/20 luminometer (Turner Designs) and the ac-
tivity was expressed as relative luminescence units
(Rlu) per Wg protein. Protein was estimated by the
Bradford assay [11]. Since all the plasmids used in
this study contained an autonomously replicating se-
quence, we took precautions to avoid discrepancies
that might result from varying copy numbers [12].
Transformants were randomly picked up, character-
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ized by Southern hybridization, and directly used for
the reporter assay without subculturing or storing.
Each experiment was repeated several times.
2.5. Gel mobility shift assay
Cell extracts were prepared as described by Sri-
kantha et al. [9]. The protein concentration of the
extracts was determined using the Bradford method
[11]. The extracts were stored at 380‡C in aliquots
and were used only once. A synthetic, 30-nucleotide
oligonucleotide, harboring the AP-1 element
(AATGTTTATGCGTGACCCAAACATAATCTC),
was procured commercially from Integrated DNA
Technologies, Inc. (Iowa, USA) and was used as a
probe for gel mobility shift assay. Labeled oligonu-
cleotide was incubated with 5^10 Wg cell extracts at
room temperature for 20 min and the complexes
formed were resolved on a 7% polyacrylamide gel
with 0.5UTBE as the running bu¡er. For competi-
tion experiments 50^100-fold molar excess of cold
double-stranded oligonucleotide was added to the
incubation mixture prior to the addition of the
probe.
3. Results and discussion
3.1. Identi¢cation of the transcription start site and
the TATA element of the CDR1 promoter
The CDR1 gene, isolated previously [13], contains
a 1210-bp sequence upstream of its initiation codon
(see Fig. 1A). In order to analyze the regulation of
its expression by various agents, we delineated its
promoter by ¢rst identifying the transcription initia-
tion site. A synthetic 21-bp oligonucleotide comple-
mentary to a region spanning the 5P end of the cod-
Fig. 1. A: Nucleotide sequence of the 1.1-kb upstream region of the CDR1 gene (reproduced from Prasad et al. [13]). The putative
TATA element along with a number of other cis-regulatory elements are identi¢ed. YAP-1: yeast AP-1; AP-1: mammalian AP-1; HSE:
heat shock element; MDR-NF-1: MDR nuclear factor 1; +1: transcription start site. B: Mapping of the transcription start point of
CDR1 promoter was carried out by extending a 21-mer synthetic oligonucleotide primer complementary to the underlined sequence in A.
The transcription start site at 63 nucleotides upstream of the ¢rst ATG is identi¢ed by an asterisk. EP: extension product.
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ing sequence (see Fig. 1A) was used to perform a
primer extension analysis using total RNA isolated
from C. albicans cells treated with miconazole, a po-
tent inducer of CDR1. The radiolabeled primer was
extended to a 63-nucleotide product (Fig. 1B). The
same product in a much lower amount was also ob-
tained when cells were not treated with the drug
(data not shown). Therefore, it established that the
transcription of the CDR1 gene is initiated 63 nu-
cleotides upstream of the coding sequence. In yeast,
the transcription start site is generally located at
40^120 bp downstream of the TATA sequence [14]
and in conformity with this pattern, the CDR1 tran-
scription start site is also preceded by a TATA se-
quence 52 bp upstream (see Fig. 1A). We thus con-
clude that this TATA sequence is the functional
Fig. 2. The CDR1 promoter consists of multiple regulatory domains. A: The 5P deleted promoter-Rluc recombinants were transformed in
C. albicans cells and assayed for luciferase expression. Promoter activity expressed as luminescence (Rlu Wg31 protein) are an average of
six independent experiments done in duplicate. The relative promoter activity, taking that of the full-length promoter as 1, is shown in pa-
rentheses. Each number shown in the diagram denotes the end point of deletion. B: The drug-responsive regions are clustered in the prox-
imal promoter. The v345 bp promoter-luciferase recombinant was tested for its responsiveness to various stresses as shown above. Mic:
miconazole (100 Wg ml31 ; 1 h); Flu: £uconazole (50 Wg ml31 ; 1 h); Estra: L-estradiol (1 mM; 15 min); Pro: progesterone (1 mM;
15 min); Heat: 42‡C exposure (15 min); Cyh: cycloheximide (1 Wg ml31 ; 1 h); CdCl2 : cadmium chloride (0.5 mM; 1 h); UI stands for
uninduced cells.
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TATA element of the CDR1 promoter. As shown in
Fig. 1A, sequence analysis of this 1.14-kb promoter
fragment using the TRANSFAC program (BCM
Search Launcher) revealed the presence of a number
of cis-regulatory elements such as AP-1, YAP-1
(yeast AP-1), HSE (heat shock element), MDR-
NF1 (MDR nuclear factor-1, also known as drug
response element, DRE).
3.2. The CDR1 promoter is composed of multiple
upstream activating (UAS) and upstream
repressing (URS) sequence domains and the
drug-responsive domains are clustered in the
proximal promoter
We have earlier reported the upregulation of the
CDR1 transcript in response to various stresses in-
cluding drugs and steroids [6]. In order to identify
the cis-regulatory domains involved in its regulation,
a series of 5P deletion mutants were constructed (see
Section 2 for details). Each mutant was then tested
for its relative level of expression as against that of
the full-length promoter. As shown in Fig. 2A, dele-
tion of the region spanning nucleotides 31147 to
3857 resulted in a more than 15-fold increase in
CDR1 promoter-driven luciferase activity indicating
the presence of a strong negative regulatory domain
(URS1) within this region. Upon further deletion to
position 3770, the activity was further increased by
¢ve-fold (100-fold compared to full-length promoter
activity), indicating the presence of another potent
negative regulatory domain (URS2) causing a sub-
stantial repression in the activity of the native pro-
moter. Upon further deletion to 3521 bp, the activ-
ity was drastically reduced to one third of the
original. This reduction in activity was due to the
loss of two domains, one located upstream of
3696 and the other between 3696 ad 3521 bp (see
Fig. 2A), both presumably harboring upstream acti-
vation sequences (UAS1 and UAS2). Subsequent de-
letions also identi¢ed the presence of two more neg-
ative (URS3 and URS4) and one more positive
regulatory domains (UAS3) located between 3521
and 3345 bp. Another positive regulatory domain
(UAS4) was also located between 3345 and 398.
It appears from the reporter analyses of the sequen-
tially deleted promoter fragments that the CDR1
promoter is highly modular in nature, containing at
least four potent positive (UAS) and four negative
(URS) regulatory domains evenly distributed along
the entire promoter fragment. Such a modular na-
ture of promoters has earlier been shown in S. cer-
evisiae. Although, based on sequence homology to
their counterparts in S. cerevisiae, UAS-like elements
have earlier been suggested in C. albicans, this is the
¢rst experimental evidence of the existence of such
regulatory elements in a C. albicans promoter.
Nevertheless, the physiological role of these regula-
tory domains is not apparent yet and is likely to be a
component of its responsiveness to various stresses.
In order to identify the functionality of these do-
mains in the context of upregulation of CDR1 by
various drugs, the promoter recombinants were
then tested for their response to a number of drugs.
As shown in Fig. 2B, the proximal promoter, carry-
ing a deletion to position 3345 bp, was inducible by
steroids (L-estradiol and progesterone), a heavy met-
al (Cd2) and several other drugs except miconazole.
It is pertinent to mention here that the full-length
promoter also responded to all these agents in a
similar manner (data not shown).
3.3. Miconazole induction of CDR1 is mediated by an
upstream domain harboring an AP-1 element
While the full-length CDR1 promoter (31147) is
responsive to miconazole, the truncated (3345) pro-
moter is independent of miconazole induction (Fig.
2B). Therefore, in order to locate the putative mico-
nazole-responsive domain in the CDR1 promoter,
the promoter-luciferase recombinants, as described
above, were tested for their activity in the absence
and presence of miconazole. As shown in Fig. 3A,
the full-length promoter (31147) was induced by
miconazole to the extent of 3.5-fold. However, dele-
tion of about 250 bp from its 5P end (to 3857) re-
sulted in the complete loss of the miconazole re-
sponse. All the subsequent deletion mutants failed
to be induced by the drug and the response by one
of them, v452, is shown in Fig. 3A as a representa-
tive. The sequence analysis of this region (31147 to
3857) of the promoter revealed the presence of one
YAP-1 and an AP-1 like element (see Fig. 1A).
While the YAP-1 sequence shows a considerable de-
gree of degeneracy [15], the mammalian AP-1
(TGACTCA) is highly conserved and the AP-1 se-
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quence in the miconazole response region (TGACC-
CA) has six out of seven bases identical to the mam-
malian AP-1. Nonetheless, the yeast AP-1(s) binds to
both YAP and mammalian AP-1 sequences albeit
with di¡erent e⁄ciency [15]. Since the yeast homo-
logues of AP-1 (YAPs/CAP) have already been im-
plicated in stress response [15,16], we designed a
double-stranded oligonucleotide harboring the
AP-1-like sequence (TGACCCA) in the miconazole
response domain and used it as a probe for gel mo-
bility shift analysis using extracts from miconazole-
treated cells. As shown in Fig. 3B, following mico-
nazole induction for 1 h, one of the AP-1 binding
complexes (C1) was strongly induced (compare lane
1 with lane 3) whereas the other two complexes (C2
and C3) remained una¡ected. This complex (C1) was
competitively inhibited when a 50-fold molar excess
of the unlabeled oligonucleotide was used. These re-
sults con¢rm the speci¢city of the DNA-protein in-
teraction involving the AP-1-like factor. In order to
test the nature of this binding activity, we also chal-
lenged it with an excess of unlabeled mammalian
AP-1 binding sites and that resulted in substantial
disappearance of C1 (data not shown). Thus it is
anticipated that the miconazole response to the
CDR1 promoter is mediated by the AP-1 element
present in the upstream region of the promoter.
Yeast AP-1 factors, like their mammalian counter-
parts, have been shown to activate gene expression in
response to a variety of extracellular stimuli. In par-
ticular, these factors are required for the response to
oxidative stress and for surviving exposure to a vari-
ety of cytotoxic agents, viz. heavy metal ions [17].
The involvement of AP-1 in drug resistance has al-
ready been shown in S. cerevisiae [16], Schizosaccha-
romyces pombe [18], Histoplasma capsulatum [19] and
C. albicans [5,8]. Since another AP-1-like binding site
(YAP-1) is also present in the proximal region of the
promoter (see Fig. 1A), the basis of the speci¢city of
action of the distal AP-1-like element is not clear yet.
It is likely that some additional elements in conjunc-
tion with the respective AP-1 sites might also con-
tribute to its speci¢city.
Our data unambiguously establish that the 1.14-kb
Fig. 3. Identi¢cation of a miconazole-responsive domain in the CDR1 promoter. A: The deletion constructs as described in Fig. 2A were
assayed before and after miconazole induction (100 Wg ml31 for 1 h). For comparison, the luciferase activity shown by the uninduced
full-length promoter was taken as 100 and that shown by others was expressed accordingly. The fold change as against the corresponding
control (uninduced) is mentioned on each bar. B: Stimulation of AP-1 binding activity following miconazole induction. A synthetic oligo-
nucleotide harboring the upstream AP-1 sequence (see Fig. 1A for details) was used as the probe to perform gel mobility shift assay as
described in Section 2. Among three complexes formed, only the C1 complex was strongly induced by miconazole treatment and it was
competed out by a 50-fold molar excess of unlabeled oligonucleotide.
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upstream fragment of the CDR1 gene represents its
promoter that mimics its response to a wide spec-
trum of agents such as drugs, human steroid hor-
mones and cadmium ion. Further dissection of the
promoter revealed a complex array of regulatory el-
ements distributed evenly along the entire regulatory
region. It appears from the reporter analysis of the
sequentially deleted promoter fragments that the
CDR1 promoter is highly modular in nature. The
detailed analysis of these regulatory elements is the
theme of our current research.
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